Stay updated on Pembrolizumab Combo in Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Lung Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The new page shows minor UI/layout adjustments (spacing and header ordering); core content such as eligibility criteria, interventions, and outcomes is unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-10-28T02:40:54.000Z thumbnail image
  3. Check
    32 days ago
    Change Detected
    Summary
    - Added a government-operation notice and status links, clarifying potential delays and current NIH Clinical Center openness. - Removed the previous version tag (v3.1.0) and introduced v3.2.0.
    Difference
    2%
    Check dated 2025-10-06T16:02:45.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    Changed the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.
    Difference
    0.1%
    Check dated 2025-09-29T09:57:09.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Version bumped from v3.0.1 to v3.0.2; removal of 'Back to Top' is a minor UI cleanup with no change to core content.
    Difference
    0.1%
    Check dated 2025-09-15T00:22:14.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.
    Difference
    0.1%
    Check dated 2025-09-07T20:51:15.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has been updated to include new drug information for Pembrolizumab and other related compounds, while significant content related to lung cancer and various antineoplastic agents has been removed.
    Difference
    6%
    Check dated 2025-08-31T12:56:35.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Lung Cancer Clinical Trial page.